Refrigeratory's Main Body of COVID-19 Inactivated Vaccine Expansion Project in Wuhan Completed

Construction of the refrigeratory's main body of the COVID-19 expansion project of Wuhan Institute of Biological Products Co., Ltd. for inactivated vaccine in Wuhan, Central China's Hubei Province, was completed on May 10.

The refrigeratory is built in several layers including SBS water-proof and high-density XPS thermal insulation layers.

The wall and ceiling were also built with PIR boards with wide temperature range, low thermal conductivity and good fireproof performance, making the refrigeratory a completely enclosed "box" to keep the temperature low.

High-tech materials and smart methods were used in the construction and a world-leading electronic expansion valve is installed to accurately control refrigerant input.

A smart defrosting system is also adopted in the refrigeratory to minimize the impact of defrosting on temperature.

Located in the Jingang Industrial Park in Jiangxia District, the project has a total building area of 141,000 square meters and includes an animal library, a refrigeratory, a packaging workshop, a normal-temperature warehouse and a waste storage area.

Contracted by China Construction Third Engineering Bureau Group Co., Ltd, the project is one of the two COVID-19 inactivated vaccine production lines of China National Pharmaceutical Group Co. Ltd. (Sinopharm). The other one is in Beijing.

Upon completion, the project is expected to produce 1 billion doses of COVID-19 inactivated vaccines annually, which will support safe, effective and high-quality products for general public vaccination and consolidate a defense line against the pandemic.

It is of great significance to construction of the most complete full biological product chain in Central China and is expected to contribute to Wuhan's plan of building a health industrial cluster.

(Executive editor: Wang Ruoting)